Adaptimmune Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:ADAP Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
17 Jan 24	SellUS$15,889	John Lunger	Individual	22,795	US$0.79
17 Jan 24	SellUS$16,423	William Bertrand	Individual	23,589	US$0.79
17 Jan 24	SellUS$27,594	Adrian G. Rawcliffe	Individual	39,384	US$0.79
17 Jan 24	SellUS$14,106	Elliot Norry	Individual	20,563	US$0.79
12 Jan 24	SellUS$24,734	Adrian G. Rawcliffe	Individual	29,202	US$0.85
12 Jan 24	SellUS$10,015	Elliot Norry	Individual	11,808	US$0.85
12 Jan 24	SellUS$7,813	John Lunger	Individual	9,229	US$0.85
12 Jan 24	SellUS$7,813	William Bertrand	Individual	9,229	US$0.85
01 Sep 23	SellUS$1,874	Adrian G. Rawcliffe	Individual	2,403	US$0.78
01 Aug 23	SellUS$2,804	John Lunger	Individual	3,096	US$0.91
10 Jul 23	SellUS$43,447	Garry Menzel	Individual	47,702	US$0.91
27 Jun 23	SellUS$2,146	Adrian G. Rawcliffe	Individual	2,333	US$0.92

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of ADAP?
Owner Type	Number of Shares	Ownership Percentage
Private Companies	10,664	0.00417%
Individual Insiders	1,753,808	0.686%
VC/PE Firms	33,329,778	13%
General Public	38,507,870	15.1%
Institutions	88,172,054	34.5%
Hedge Funds	93,787,805	36.7%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 54.2%.

Top Shareholders

Top 25 shareholders own 83.32% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
21.5%	EcoR1 Capital, LLC	54,813,620	US$56.5m	0%	1.86%
15.3%	Matrix Capital Management Company, LP	38,974,185	US$40.1m	0%	0.38%
13%	New Enterprise Associates, Inc.	33,329,778	US$34.3m	95.1%	1.97%
6.23%	Baillie Gifford & Co.	15,912,140	US$16.4m	0%	0.01%
4.73%	Long Focus Capital Management LLC	12,086,915	US$12.4m	10.3%	1.77%
4.29%	Baker Bros. Advisors LP	10,969,282	US$11.3m	0%	0.16%
4.08%	PFM Health Sciences, LP	10,423,135	US$10.7m	0%	0.73%
2.17%	MPM Asset Management, L.L.C.	5,555,461	US$5.7m	-11.6%	2.56%
1.99%	BioImpact Capital LLC	5,095,912	US$5.2m	0%	1.27%
1.84%	Bank of America Corporation, Asset Management Arm	4,696,954	US$4.8m	0.02%	no data
1.72%	Tang Capital Management, LLC	4,387,238	US$4.5m	-15.1%	0.54%
1.33%	Citadel Advisors LLC	3,399,514	US$3.5m	-4.23%	no data
0.95%	Rock Springs Capital Management LP	2,425,468	US$2.5m	-13%	0.08%
0.77%	Morgan Stanley, Investment Banking and Brokerage Investments	1,956,373	US$2.0m	-4.42%	no data
0.62%	Impresa Management LLC	1,578,783	US$1.6m	0%	0.65%
0.54%	Syncona Investment Management Limited	1,377,294	US$1.4m	0%	0.42%
0.54%	Renaissance Technologies LLC	1,370,239	US$1.4m	33.3%	no data
0.36%	JP Morgan Asset Management	928,224	US$956.1k	0%	no data
0.28%	Redmile Group, LLC	715,607	US$737.1k	0%	0.03%
0.27%	Garry Menzel	686,295	US$706.9k	0%	no data
0.2%	GSA Capital Partners LLP	508,808	US$524.1k	0%	0.05%
0.19%	Acuitas Investments, LLC	479,789	US$494.2k	0.01%	0.2%
0.17%	Millennium Management LLC	441,032	US$454.3k	47%	no data
0.17%	Rathbones Investment Management Limited	432,818	US$445.8k	0%	no data
0.15%	U.S. Global Investors, Inc.	382,553	US$394.0k	0%	0.02%